LDL / HDL Ratio: Understanding Your Blood Test Series

1. Overview: What this test reveals and why it is important

The LDL / HDL ratio is calculated by dividing low‑density lipoprotein cholesterol (LDL‑C) by high‑density lipoprotein cholesterol (HDL‑C). It was historically promoted as a single number capturing both pro‑atherogenic and anti‑atherogenic cholesterol fractions. A lower ratio was considered favourable, reflecting fewer LDL particles relative to HDL particles.

However, contemporary cardiovascular guidelines have moved away from using the LDL/HDL ratio as a treatment target. This shift occurred because:

· LDL‑C is a causal risk factor; lowering it consistently reduces events regardless of baseline HDL.

· Pharmacologically raising HDL‑C has failed to improve outcomes in large randomised trials.

· Non‑HDL cholesterol (total cholesterol minus HDL) and apolipoprotein B are superior risk markers, particularly when triglycerides are elevated or LDL‑C is not markedly high.

Nevertheless, the LDL/HDL ratio remains widely reported on laboratory reports and may still be encountered in clinical practice. It provides a quick snapshot of the balance between atherogenic and protective lipoproteins, and extreme values carry prognostic information. A high ratio indicates a predominance of LDL particles; a low ratio suggests a favourable lipoprotein profile.

Current role: The LDL/HDL ratio is a risk marker, not a therapeutic target. It can be used for motivational counselling and global risk communication, but treatment decisions should be based primarily on LDL‑C, non‑HDL‑C, and absolute cardiovascular risk assessment.

---

2. What does it measure

a. Units of measurement

· Dimensionless ratio – calculated as LDL‑C (mg/dL or mmol/L) ÷ HDL‑C (mg/dL or mmol/L).

· Since both numerator and denominator share the same unit, the ratio is unit‑free.

b. Normal Range and Optimal Targets

(Reference values are derived from epidemiological cohorts; they vary by sex, age, and cardiovascular risk status.)

Optimal (low risk):

· Men: less than 2.5

· Women: less than 2.0

Moderate risk:

· Men: 2.5–3.5

· Women: 2.0–3.0

High risk:

· Men: greater than 3.5

· Women: greater than 3.0

Very high risk (often associated with established ASCVD or diabetes):

· Greater than 4.0 in either sex

Interpretation notes:

· A ratio below 2.0 is generally considered excellent.

· A ratio above 4.0 indicates a marked predominance of LDL and is associated with significantly increased cardiovascular risk.

· The ratio does not distinguish between isolated LDL elevation, isolated HDL deficiency, or combined abnormalities.

· Treatment decisions should never be based solely on this ratio; LDL‑C and global risk assessment are paramount.

---

3. Other factors connected to this

a. Direct correlation (factors that directly raise the LDL/HDL ratio)

Factors that increase LDL (numerator) or decrease HDL (denominator) will raise the ratio.

Factors that raise LDL‑C:

· Dietary: high intake of saturated fats, trans fats, dietary cholesterol.

· Genetic: familial hypercholesterolaemia, familial combined hyperlipidaemia, polygenic hypercholesterolaemia.

· Secondary: hypothyroidism, nephrotic syndrome, cholestasis, obesity.

· Medications: thiazide diuretics, ciclosporin, amiodarone, some progestins.

Factors that lower HDL‑C:

· Lifestyle: smoking, physical inactivity, high glycaemic load diets, excess refined carbohydrates.

· Metabolic: insulin resistance, type 2 diabetes, obesity (especially visceral), hypertriglyceridaemia.

· Genetic: familial hypoalphalipoproteinaemia, Tangier disease, LCAT deficiency.

· Medications: androgens, anabolic steroids, progestins, beta‑blockers (non‑vasodilating), thiazide diuretics.

Thus, the LDL/HDL ratio is increased by:

· Unhealthy dietary patterns (high saturated fat, high sugar, low fibre).

· Smoking, sedentary lifestyle.

· Insulin resistance, metabolic syndrome, diabetes.

· Hypothyroidism, chronic kidney disease.

· Genetic dyslipidaemias affecting LDL or HDL.

b. Indirect correlation (factors that influence the ratio independently or through assay issues)

· Age: LDL tends to rise until middle age then plateau; HDL declines slightly with age; ratio increases.

· Sex: premenopausal women have higher HDL and lower LDL than men; ratio is naturally lower.

· Pregnancy: LDL rises, HDL rises slightly; ratio may increase modestly; not assessed during pregnancy.

· Menopause: LDL increases, HDL declines; ratio rises.

· Ethnicity: South Asians often have higher LDL and lower HDL for same metabolic parameters; ratio tends to be higher.

· Acute illness / inflammation: LDL falls, HDL falls as negative acute phase reactants; ratio may be unpredictably affected. Do not test during acute illness.

· Medications:

· Statins lower LDL, may slightly raise HDL → ratio improves.

· Fibrates lower LDL modestly, raise HDL → ratio improves.

· Niacin raises HDL, lowers LDL → ratio improves (but drug not recommended).

· Oestrogen raises HDL, lowers LDL → ratio improves.

· Fasting status: Minimal effect on ratio if both LDL and HDL are measured non‑fasting; however, calculated LDL may be inaccurate if triglycerides >400 mg/dL, affecting ratio reliability.

---

4. Disorders related to abnormal values

a. When the ratio is elevated (pro‑atherogenic state)

· Atherosclerotic cardiovascular disease (ASCVD): coronary artery disease, stroke, peripheral arterial disease. Elevated ratio is a marker of increased risk.

· Familial hypercholesterolaemia: markedly elevated LDL, normal or low HDL → ratio often >4.0–5.0.

· Familial combined hyperlipidaemia: elevated LDL and/or triglycerides, low HDL → ratio elevated.

· Metabolic syndrome / insulin resistance / type 2 diabetes: low HDL, normal or moderately elevated LDL (often small dense particles) → ratio elevated.

· Obesity, sedentary lifestyle, smoking.

· Hypothyroidism, chronic kidney disease, nephrotic syndrome.

· Medication‑induced dyslipidaemia (e.g., thiazides, beta‑blockers, progestins).

b. When the ratio is low (potentially protective, but can be pathological)

· Low ratio is generally desirable (high HDL, low LDL).

· Pathologically low LDL (hypobetalipoproteinaemia, abetalipoproteinaemia) – ratio very low, but not protective if LDL is extremely low due to genetic disease; may be associated with fat malabsorption, neurological deficits.

· Pathologically high HDL (CETP deficiency) – ratio very low; however, HDL may be dysfunctional and cardiovascular risk not necessarily reduced.

· Severe hyperthyroidism – lowers LDL, may raise HDL → ratio decreases.

· Malnutrition / advanced liver disease – reduced synthesis of all lipoproteins.

· High‑intensity statin therapy – intentional therapeutic lowering of LDL, often with mild HDL increase → ratio decreases (desired).

---

5. Best way to address aberrant levels

Important principle: The LDL/HDL ratio is not a treatment target. Intervention should focus on lowering LDL‑C to guideline‑recommended goals based on absolute cardiovascular risk, and on addressing the metabolic causes of low HDL (exercise, weight loss, smoking cessation, glycaemic control). Treat the underlying dyslipidaemia, not the ratio.

a. Quick ways or using Medications

Medications that lower LDL‑C (and thus improve the ratio):

· Statins – first‑line for LDL reduction; modest HDL increase.

· Ezetimibe – LDL reduction; neutral effect on HDL.

· PCSK9 inhibitors – potent LDL reduction; mild HDL increase.

· Bempedoic acid – LDL reduction; neutral HDL effect.

Medications that raise HDL‑C (modestly):

· Fibrates – particularly in hypertriglyceridaemia; modest HDL increase.

· Niacin – effective but no longer recommended due to lack of outcome benefit and adverse effects.

Medications that lower triglycerides and may improve HDL:

· Fibrates, icosapent ethyl (prescription EPA), statins (modest).

Do not self‑prescribe – all lipid‑modifying medications require medical supervision.

b. Using Supplements or Holistic medicine

For improving the ratio (lowering LDL and/or raising HDL):

· Omega‑3 fatty acids (EPA/DHA):

· Lower triglycerides, modest LDL increase in some patients, minimal HDL increase.

· Preferred source: Algae oil – sustainable, plant‑based, direct EPA/DHA, no marine contaminants.

· Avoid conventional fish oil (overfishing, ocean pollution, ethical concerns).

· Dose: 2–4 g/day EPA/DHA for triglyceride effect; lower doses for general health.

· Form: re‑esterified triglyceride for optimal absorption.

· Plant sterols and stanols:

· Lower LDL‑C by 8–15%; no effect on HDL.

· Preferred source: derived from vegetable oils (soy, pine tree oil).

· Dose: 2 g/day with meals.

· Soluble fibre:

· Psyllium, beta‑glucans (oats, barley), glucomannan – lower LDL‑C by 5–10%; minimal HDL effect.

· Target: 10–25 g/day soluble fibre.

· Berberine:

· Lowers LDL‑C and triglycerides; modest HDL increase.

· Preferred source: Standardised berberine (≥97%) from Berberis aristata or Phellodendron amurense.

· Dose: 500 mg twice daily.

· Caution: GI side effects, drug interactions; avoid in pregnancy.

· Red yeast rice:

· Contains monacolin K (natural lovastatin); lowers LDL‑C by 15–25%.

· Caution: Potency variability, citrinin contamination risk; requires medical oversight.

· Avoid products with added synthetic folic acid or cyanocobalamin.

· Green tea extract (EGCG):

· Modest LDL and triglyceride reduction; minimal HDL effect.

· Use beverage (2–3 cups/day) rather than concentrated extracts (hepatotoxicity risk).

· Vitamin D:

· Deficiency linked to dyslipidaemia; supplementation may modestly improve lipid profile.

· Preferred: D3 (cholecalciferol) from lichen.

· Magnesium:

· Deficiency associated with low HDL, elevated LDL; supplementation may improve ratio.

· Preferred forms: glycinate, citrate, malate.

· Garlic (Allium sativum):

· Aged garlic extract; small LDL‑C reduction.

Supplements with no consistent evidence or not recommended:

· Niacin – not recommended as supplement.

· Policosanol – ineffective.

· Coconut oil – raises LDL; avoid.

Ayurvedic approaches:

· Guggulu (Commiphora mukul) – standardised guggulsterones; modest lipid‑lowering, but efficacy debated and hepatotoxicity concerns.

· Arjuna (Terminalia arjuna) – limited evidence.

· Always consult a qualified practitioner; herbs can interact with statins and anticoagulants.

c. Using Diet and Foods (following a plant‑forward, ecologically sustainable approach)

Diet is the foundation for improving the LDL/HDL ratio – primarily by lowering LDL‑C and secondarily by addressing lifestyle factors that suppress HDL.

Core dietary pattern – what to emphasise:

· Whole food, plant‑based (WFPB) or Mediterranean‑style plant‑forward diet – strongest evidence for cardiovascular risk reduction.

· Replace saturated fats with unsaturated fats:

· Extra virgin olive oil as principal fat.

· Nuts and seeds: walnuts, almonds, pistachios, flaxseeds, chia seeds, hemp seeds.

· Avocado.

· Increase soluble fibre:

· Oats, barley, psyllium, eggplant, okra, legumes (lentils, chickpeas, beans).

· Target 25–40 g total fibre daily, with 10–20 g soluble fibre.

· Emphasise whole grains – quinoa, brown rice, whole wheat, millets.

· Limit refined carbohydrates and added sugars – reduce VLDL/triglycerides, improve HDL.

· Avoid trans fats – completely.

Specific foods with evidence for improving the ratio:

· Oats and barley – beta‑glucan (3 g/day) lowers LDL.

· Legumes – lentils, chickpeas, beans – ½ cup daily lowers LDL.

· Nuts – 30 g/day lowers LDL, modestly raises HDL.

· Soy protein – 25 g/day (tofu, tempeh, edamame) lowers LDL.

· Plant sterol‑enriched foods – fortified margarines, yoghurt drinks.

· Olive oil – 2 tablespoons (20 g) extra virgin daily.

· Avocado – one half to one daily lowers LDL.

· Green tea – 2–3 cups/day.

· Dark chocolate (≥70% cocoa) – flavonoids; limit added sugar.

Lifestyle factors more potent than diet for raising HDL:

· Aerobic exercise – 30–60 minutes, most days, raises HDL by 5–15%.

· Weight loss – 5–10% reduction significantly increases HDL.

· Smoking cessation – HDL rises within weeks.

What to avoid or severely limit:

· Saturated fats – coconut oil, palm oil, butter, cream, cheese, fatty meats.

· Trans fats – partially hydrogenated oils.

· Red and processed meats – not required.

· Refined carbohydrates and added sugars – soft drinks, fruit juices, sweets, pastries.

· Excess alcohol – moderate intake raises HDL but not recommended as intervention; heavy intake harms liver.

Protein sources (hierarchy adhered):

· Plant‑based (primary): legumes, soy products (tofu, tempeh, edamame), seitan.

· Fungi / algae (encouraged): mycoprotein (Quorn), spirulina, chlorella.

· Biotechnology / lab‑grown (acceptable): precision‑fermented dairy proteins (animal‑free whey, casein).

· Dairy / eggs (permitted but not emphasised): low‑fat fermented dairy (yoghurt, kefir) if tolerated; full‑fat dairy contains saturated fat.

· Meat, poultry, fish: deliberately omitted. Effective plant‑based alternatives exist to meet all nutritional requirements for improving the LDL/HDL ratio. There is no need for animal products to achieve optimal lipoprotein balance.

---

6. How soon can one expect improvement and the ideal time frame to retest

For dietary and lifestyle interventions:

· LDL reduction: begins within 2–4 weeks; maximal effect by 3–6 months.

· HDL increase: slower; detectable after 8–12 weeks of sustained exercise or weight loss.

· Ratio improvement: typically seen in 2–3 months and continues over 6–12 months.

For supplements:

· Plant sterols, soluble fibre, berberine: LDL reduction in 4–8 weeks.

· Omega‑3 (algae oil): triglyceride reduction in 6–12 weeks; modest HDL effect.

For medications:

· Statins, ezetimibe: LDL reduction in 4–6 weeks; maximal effect at 6–8 weeks.

· PCSK9 inhibitors: 4–8 weeks.

· Fibrates: HDL increase in 4–8 weeks.

Retesting interval:

· Initiation or dose change of lipid‑lowering therapy: repeat lipid panel in 6–12 weeks.

· Lifestyle intervention alone: repeat in 3–6 months.

· At goal: annually, or more frequently if very high risk.

· Do not retest more often than every 4 weeks – meaningful change does not occur faster.

---

Conclusion

The LDL/HDL ratio is a relic of an era when we viewed cardiovascular risk through a simple see‑saw of good and bad cholesterol. We now understand that LDL is the driver, HDL is an accompanying passenger, and the ratio is at best a crude approximation of risk.

Today, the ratio serves two modest purposes: as a communication tool for patients and as an epidemiological shorthand. It should never dictate therapy. The clinician's duty is to lower LDL‑C to evidence‑based targets, to counsel smoking cessation, exercise, and weight loss, and to control the metabolic derangements that suppress HDL and elevate triglycerides.

A plant‑based, ecologically responsible diet – legumes, whole grains, nuts, seeds, olive oil, and algae‑derived omega‑3s – accomplishes all of these goals. It lowers LDL, improves HDL function, reduces triglycerides, and sustains the planet. Meat is not required; its omission is both clinically sound and ecologically necessary.

The ratio will improve as a consequence of treating the patient, not the number.

---x---x

Note on dietary recommendations on this site:

For the sake of our environment we adhere to the following dietary preference hierarchy:

1. Plant‑based

2. Fungi / algae / fermented

3. Biotechnology / lab‑grown / cultures

4. Dairy / eggs

5. Meat / fish / poultry (only if no effective alternative exists)

This approach reflects ecological responsibility, antibiotic stewardship, and the urgent need to reduce the environmental footprint of dietary recommendations.

-x-x